AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32277343 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-and-extend protocol with moderate extensions (T&Em)
Number of subjects: 52
Study 32277343 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-and-extend protocol with rapid extensions (T&Er)
Number of subjects: 52
Study 32277343 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 52
Study 34275865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional-incentive arm (US$50 plus US$0.20 incentive per client visiting mobile-outreach services)
Number of subjects: 7146
Study 34275865 — intervention group
Group type: COMPARATOR
Intervention: Non-incentive arm (one-off US$50 remuneration per CBD)
Number of subjects: 7146
Study 34275865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional-incentive arm
Number of subjects: 7146
Study 34275865 — intervention group
Group type: COMPARATOR
Intervention: Non-incentive arm
Number of subjects: 7146
Study 34275865 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST clinics during distribution
Number of subjects: 7146
Study 34275865 — intervention group
Group type: COMPARATOR
Intervention: Non-HIVST clinics
Number of subjects: 7146
Study 35871702 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate gel (UltraEZ)
Number of subjects: 54
Study 35871702 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) with a low-level infrared laser (100 mW, spot size of 0.028 cm2, dose of 1 J per point)
Number of subjects: 54
Study 35871702 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate gel + PBM
Number of subjects: 54
Study 32075440 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 44
Study 32075440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32075440 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac
Number of subjects: 44
Study 32075440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IV acetaminophen and IV ketorolac
Number of subjects: 44
Study 35820741 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy with natural thermal mineral water (38°C)
Number of subjects: 130
Study 35820741 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral water baths (30°C-32°C)
Number of subjects: 130
Study 34570798 — intervention group
Group type: EXPERIMENTAL
Intervention: Video of Trump endorsing the vaccine
Number of subjects: 387
Study 34570798 — intervention group
Group type: COMPARATOR
Intervention: Public health expert excerpt
Number of subjects: 387
Study 35877092 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive telehealth intervention (n = 101)
Number of subjects: 200
Study 35877092 — intervention group
Group type: COMPARATOR
Intervention: Telemonitoring and care coordination (n = 99)
Number of subjects: 200
Study 35877092 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive telehealth intervention
Number of subjects: 200
Study 35877092 — intervention group
Group type: COMPARATOR
Intervention: Telemonitoring and care coordination
Number of subjects: 200
Study 32067288 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (50 mg daily for 4 weeks)
Number of subjects: 25
Study 32067288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 36113914 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-judgmental mirror gazing task
Number of subjects: 125
Study 36113914 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgmental mirror gazing task
Number of subjects: 125
Study 33792743 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA testing in study arm A
Number of subjects: 23301
Study 32902102 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold alloy abutments
Number of subjects: 17
Study 32902102 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium, titanium-base, and zirconia abutments
Number of subjects: 17
Study 32902102 — intervention group
Group type: COMPARATOR
Intervention: All abutment materials
Number of subjects: 17
Study 36278773 — intervention group
Group type: EXPERIMENTAL
Intervention: AT plus WC (group A)
Number of subjects: 40
Study 36278773 — intervention group
Group type: EXPERIMENTAL
Intervention: AT plus WC plus CsA 0.05% (group B)
Number of subjects: 40
Study 33027815 — intervention group
Group type: EXPERIMENTAL
Intervention: RO4929097
Number of subjects: 47
Study 33971278 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU bolus dose of vitamin D plus 1000 IU daily supplement for six weeks
Number of subjects: 22
Study 33971278 — intervention group
Group type: COMPARATOR
Intervention: 1000 IU daily supplement alone
Number of subjects: 22
Study 616781077 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical cricothyrotomy technique
Number of subjects: 11
Study 616781077 — intervention group
Group type: COMPARATOR
Intervention: Portex Cricothyrotomy Kit
Number of subjects: 11
Study 616781077 — intervention group
Group type: COMPARATOR
Intervention: Melker Cricothyrotomy kit
Number of subjects: 11
Study 34321042 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-supported sitting balance therapy (12 sessions of 50 min over four weeks)
Number of subjects: 30
Study 34321042 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 30
Study 33258933 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic information system-based geosurvey and field mapping system
Number of subjects: 25221
Study 35924472 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-electrode (ME) catheter
Number of subjects: 136
Study 32887732 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with flexible sigmoidoscopy (with a repeat screening at 3 or 5 years)
Number of subjects: 2359
Study 32887732 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2359
Study 32887732 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient-boosted model prediction
Number of subjects: 2359
Study 32815439 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide
Number of subjects: 0
Study 34878659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks for ≤2 years)
Number of subjects: 94
Study 34878659 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m2 IV every week)
Number of subjects: 94
Study 33915251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 of a 21-day cycle)
Number of subjects: 503
Study 33915251 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2 on day 1)
Number of subjects: 503
Study 33915251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2)
Number of subjects: 503
Study 33915251 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2)
Number of subjects: 503
Study 34986500 — intervention group
Group type: EXPERIMENTAL
Intervention: lavender, eucalyptus and tangerine essential oils
Number of subjects: 40
Study 34986500 — intervention group
Group type: EXPERIMENTAL
Intervention: lavender, eucalyptus, tangerine and melaleuca essential oils
Number of subjects: 40
Study 34986500 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 34118964 — intervention group
Group type: COMPARATOR
Intervention: Urban schools
Number of subjects: 1332
Study 34118964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural schools
Number of subjects: 1332
Study 34118964 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial species
Number of subjects: 1332
Study 34118964 — intervention group
Group type: EXPERIMENTAL
Intervention: Human endocrine and metabolic disease pathways
Number of subjects: 1332
Study 34542079 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based training (MBT)
Number of subjects: 76
Study 34542079 — intervention group
Group type: COMPARATOR
Intervention: Cognitive rehabilitation therapy (CRT)
Number of subjects: 76
Study 34542079 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 76
Study 36094821 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) infiltration during PCNL
Number of subjects: 140
Study 36094821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infiltration during PCNL
Number of subjects: 140
Study 36184258 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Atomoxetine (ATO) + 5 mg Oxybutynin (OXY)
Number of subjects: 17
Study 36184258 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 17
Study 36384573 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation (WBI) and regional nodal irradiation (RNI)/post-mastectomy radiotherapy (PMRT)
Number of subjects: 1106
Study 36384573 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast irradiation (WBI) alone/no PMRT
Number of subjects: 1106
Study 36440985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg orally 2 hours before surgery
Number of subjects: 55
Study 36440985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 36440985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg orally
Number of subjects: 55
Study 34701225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 0
Study 34701225 — intervention group
Group type: COMPARATOR
Intervention: 3D Conformal Radiation Therapy (3DCRT)
Number of subjects: 0
Study 34701225 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 0
Study 33999650 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF-PRS (plasma proteomic risk score) derived from 681 patients in the derivation cohort.
Number of subjects: 1017
Study 33999650 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF-PRS validated in 336 patients.
Number of subjects: 1017
Study 33999650 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF-PRS adjusted for clinical score and NT-proBNP.
Number of subjects: 1017
Study 33999650 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF-PRS metrics of risk stratification.
Number of subjects: 1017
Study 33999650 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF-PRS associated with cardiovascular death and HF phenotypes.
Number of subjects: 1017
Study 35429005 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive therapy (I‐CT) for 10 weeks
Number of subjects: 19
Study 35429005 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who understood the cognitive model
Number of subjects: 19
Study 35429005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reductions in negative appraisals
Number of subjects: 19
Study 34199645 — intervention group
Group type: EXPERIMENTAL
Intervention: High LCn3 diet
Number of subjects: 0
Study 34199645 — intervention group
Group type: EXPERIMENTAL
Intervention: High LCn3 & PP diet
Number of subjects: 0
Study 34199645 — intervention group
Group type: EXPERIMENTAL
Intervention: High PP diet
Number of subjects: 0
Study 34199645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low LCn3 & PP diet
Number of subjects: 0
Study 35964063 — intervention group
Group type: COMPARATOR
Intervention: Family-based Improvement for Health Literacy (FAMILY) intervention, which includes health literacy education interventions such as project preparation, core group building, promotion within family branch, and competition between family branches.
Number of subjects: 0
Study 35964063 — intervention group
Group type: COMPARATOR
Intervention: Contracted Family Doctor Services as control measure.
Number of subjects: 0
Study 34596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for pediatricians
Number of subjects: 164
Study 34596672 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 164
Study 32521976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) 2092 kJ/day, whole protein enteral nutrition for 90 days after discharge
Number of subjects: 90
Study 32521976 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary guidance only)
Number of subjects: 90
Study 32521976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS)
Number of subjects: 90
Study 36255262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium polynucleotide
Number of subjects: 90
Study 36255262 — intervention group
Group type: COMPARATOR
Intervention: Classic hyaluronic acid
Number of subjects: 90
Study 36255262 — intervention group
Group type: COMPARATOR
Intervention: Crosslinked hyaluronic acid
Number of subjects: 90
Study 36255262 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including polynucleotide, classic hyaluronic acid, and crosslinked hyaluronic acid)
Number of subjects: 90
Study 35761370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 800 mg stat then 400 mg weekly
Number of subjects: 0
Study 35761370 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 35761370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 0
Study 33213194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FC)
Number of subjects: 111
Study 33213194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 33213194 — intervention group
Group type: COMPARATOR
Intervention: Cohort (FibTEM-MCF ≥7 mm)
Number of subjects: 111
Study 33812327 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID + magnesium (400 mg etodolac twice a day with 365 mg oral magnesium supplementation)
Number of subjects: 240
Study 33812327 — intervention group
Group type: COMPARATOR
Intervention: NSAID alone (400 mg etodolac twice a day)
Number of subjects: 240
Study 33812327 — intervention group
Group type: COMPARATOR
Intervention: NSAID + paracetamol (400 mg etodolac twice a day with 500 mg paracetamol twice a day)
Number of subjects: 240
Study 32179149 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS loading dose (LD group) of 4 mg CBA/kg/dose
Number of subjects: 20
Study 32179149 — intervention group
Group type: COMPARATOR
Intervention: Standard initial dose (NLD group) of 2.5 mg (12-h interval) or 1.7 mg (8-h interval) of CBA/kg/dose
Number of subjects: 20
Study 32179149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups monitored for acute kidney injury (AKI)
Number of subjects: 20
Study 33054505 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG with PLWDs
Number of subjects: 40
Study 33054505 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG without PLWDs
Number of subjects: 40
Study 33054505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 33054505 — intervention group
Group type: COMPARATOR
Intervention: All patients without PLWDs
Number of subjects: 40
Study 32868437 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological measures of transmission based on antibody response to S. mansoni soluble egg antigen (SEA)
Number of subjects: 3663
Study 32868437 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological measures of transmission
Number of subjects: 3663
Study 34831884 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel multicomponent (MLMC) intervention
Number of subjects: 0
Study 34831884 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sub-components of the intervention
Number of subjects: 0
Study 33506411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 5 mg/kg of Se from SeGlu
Number of subjects: 360
Study 33506411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 0.3 mg/kg of Se from sodium selenite (SS)
Number of subjects: 360
Study 33506411 — intervention group
Group type: COMPARATOR
Intervention: Basal diet alone (control group)
Number of subjects: 360
Study 35638864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation
Number of subjects: 38
Study 35638864 — intervention group
Group type: COMPARATOR
Intervention: Nasal spray
Number of subjects: 38
Study 33159220 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel AML decision aid
Number of subjects: 20
Study 32514756 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of elemental zinc for three months
Number of subjects: 60
Study 32514756 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 60
Study 35609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 239
Study 35609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 239
Study 35609978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 33068032 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical safety studies (PCSSs) included in Investigator's Brochures (IBs)
Number of subjects: 46
Study 33068032 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator's Brochures (IBs) reporting patterns
Number of subjects: 46
Study 35338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 130
Study 35338094 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 130
Study 33231752 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphyseal chin grafts
Number of subjects: 14
Study 33231752 — intervention group
Group type: COMPARATOR
Intervention: Retromolar grafts
Number of subjects: 14
Study 35838773 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation decision aid with explicit value clarification method and computer-tailored advice
Number of subjects: 2375
Study 34154634 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training of activities of daily living (ADL), resistance, and stability, twice a week for 1 hour per session
Number of subjects: 57
Study 34154634 — intervention group
Group type: COMPARATOR
Intervention: Daily home-based exercise representing regular outpatient care
Number of subjects: 57
Study 35383128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical peer review in intervention hospitals
Number of subjects: 25074
Study 35383128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clinical peer review)
Number of subjects: 25074
Study 34028460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate + rhinophototherapy
Number of subjects: 75
Study 34028460 — intervention group
Group type: COMPARATOR
Intervention: Intranasal beclomethasone dipropionate
Number of subjects: 75
Study 32948120 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing group intervention (34 bi-weekly sessions, 2 hours each for 4 months)
Number of subjects: 140
Study 32948120 — intervention group
Group type: COMPARATOR
Intervention: Regular activities proposed by the institution (Control group)
Number of subjects: 140
Study 36182594 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ10/AS10 (ezetimibe/atorvastatin 10/10 mg FDC)
Number of subjects: 454
Study 36182594 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ10/AS20 (ezetimibe/atorvastatin 10/20 mg FDC)
Number of subjects: 454
Study 36182594 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg (AS20)
Number of subjects: 454
Study 36182594 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg (AS40)
Number of subjects: 454
Study 34232510 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable glove liners made of Sympatex (SYM)
Number of subjects: 161
Study 34232510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton glove liners (COT)
Number of subjects: 161
Study 34232510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both glove liners (SYM and COT)
Number of subjects: 161
Study 34232510 — intervention group
Group type: COMPARATOR
Intervention: Previously used protective gloves (PUGs)
Number of subjects: 161
Study 32645934 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEY-ALL (whey protein, 3.1 µg B12/day)
Number of subjects: 167
Study 32645934 — intervention group
Group type: EXPERIMENTAL
Intervention: LITW (light resistance training with whey protein)
Number of subjects: 167
Study 32645934 — intervention group
Group type: COMPARATOR
Intervention: COLL (collagen, 1.3 µg B12/day)
Number of subjects: 167
Study 32645934 — intervention group
Group type: COMPARATOR
Intervention: CARB (maltodextrin, 0.3 µg B12/day)
Number of subjects: 167
Study 32645934 — intervention group
Group type: EXPERIMENTAL
Intervention: HRTW (heavy resistance training with whey protein)
Number of subjects: 167
Study 32645934 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEY (no training with whey protein)
Number of subjects: 167
Study 35931975 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 155
Study 35931975 — intervention group
Group type: COMPARATOR
Intervention: Regular medical care (Control)
Number of subjects: 155
Study 32608934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 16
Study 32608934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 36336005 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 1142
Study 36336005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1142
Study 34426397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (0.1 mg/kg)
Number of subjects: 194
Study 34426397 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 194
Study 32810504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) at 200 μg/m3
Number of subjects: 19
Study 32810504 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant pretreatment (1000 mg ascorbate for 7 days and 1200 mg N-acetylcysteine 1 day prior to exposure)
Number of subjects: 19
Study 32810504 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 19
Study 36238226 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 326
Study 33487254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat plant-based dietary intervention for 16 weeks
Number of subjects: 244
Study 34231653 — intervention group
Group type: COMPARATOR
Intervention: Resistance training using weightlifting machines (gym group)
Number of subjects: 74
Study 34231653 — intervention group
Group type: COMPARATOR
Intervention: Resistance training using free weights and elastic bands (freew group)
Number of subjects: 74
Study 34231653 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74